More than one million Americans live with Parkinson’s disease (PD). Today, after the launch of a new study, we now have a fuller picture of what impact the disease has on a family’s income, as well as our national economy.
The Michael J. Fox Foundation (MJFF), with Parkinson’s Foundation, AbbVie Inc., ACADIA Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, and Biogen Inc., along with American Parkinson Disease Association and The Parkinson Alliance commissioned a new study — The Economic Burden of Parkinson’s Disease — to estimate the economic burden of Parkinson’s in the United States. This study provides the most comprehensive assessment of the total economic burden on patients, care partners, payers, employers, healthcare systems and government programs.
The total cost of Parkinson’s is $52 billion every year, with $25.4 billion attributable to direct medical costs such as hospitalizations and medication, and $26.5 billion in non-medical costs like missed work, lost wages, early forced retirement and family caregiver time. This is nearly double previous estimates and, for the first time, accounts for the many ways Parkinson’s affects a person’s finances and their ability to participate in the labor market.